Journal article
Silent lesions on MRI imaging – Shifting goal posts for treatment decisions in multiple sclerosis
M Min, T Spelman, A Lugaresi, C Boz, DLA Spitaleri, E Pucci, F Grand’Maison, F Granella, G Izquierdo, H Butzkueven, JL Sanchez-Menoyo, M Barnett, M Girard, M Trojano, P Grammond, P Duquette, P Sola, R Alroughani, R Hupperts, S Vucic Show all
Multiple Sclerosis Journal | SAGE PUBLICATIONS LTD | Published : 2018
Abstract
Background: The current best practice suggests yearly magnetic resonance imaging (MRI) to monitor treatment response in multiple sclerosis (MS) patients. Objective: To evaluate the current practice of clinicians changing MS treatment based on subclinical new MRI lesions alone. Methods: Using MSBase, an international MS patient registry with MRI data, we analysed the probability of treatment change among patients with clinically silent new MRI lesions. Results: A total of 8311 MRI brain scans of 4232 patients were identified. Around 26.9% (336/1247) MRIs with one new T2 lesion were followed by disease-modifying therapy (DMT) change, increasing to 50.2% (129/257) with six new T2 lesions. DMT c..
View full abstractGrants
Funding Acknowledgements
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The MSBase Registry is supported by the independent MSBase Foundation Ltd, a health-related charity which is incorporated in Melbourne, Australia. The MSBase Foundation receives financial support from Biogen, Genzyme, Merck and Novartis. The funders had no role in study design, data access and analysis, decision to publish or preparation of the manuscript.